Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07062119 + unspecified VEGF antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07062119 | PF07062119|PF 07062119 | CD3 Antibody 107 | PF-07062119 is a bispecific antibody that targets CD3 on T-cells and guanylyl cyclase C (GUCY2C) to induce a cytotoxic T-lymphocyte (PMID: 31996389). | |
unspecified VEGF antibody |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04171141 | Phase I | PF-07062119 PF-07062119 + unspecified PD-1 antibody PF-07062119 + unspecified VEGF antibody | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Terminated | USA | AUS | 1 |